EW - Edwards Lifesciences Corporation
NEXT EARNINGS:
Apr 22, 2026
EPS Est: $0.68
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$96.38
DETAILS
HIGH:
$110.00
LOW:
$87.00
MEDIAN:
$95.50
CONSENSUS:
$96.38
UPSIDE:
16.97%
Market Cap:
48.38B
Volume:
3,263,314
Avg Volume:
3,854,608
52 Week Range:
65.94-87.89
Sector:
Healthcare
Industry:
Medical - Devices
Beta:
0.94
Last Dividend:
$N/A
Exchange:
NYSE
Country:
US
Employees:
15,800
IPO Date:
2000-03-27
EPS (TTM):
1.84
P/E Ratio:
46.44
Revenue (TTM):
6.07B
Total Assets:
13.06B
Total Debt:
700.00M
Cash & Equiv:
3.05B
Rev Growth (5Y):
6.7%
EPS Growth (5Y):
6.9%
FCF Growth (5Y):
-20.3%
ROCE:
11.0%
Debt/Equity:
0.07
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-10 | $0.58 | $0.62 | -6.3% | $1.6B | $1.5B | +1.5% |
| 2025-10-30 | $0.67 | $0.60 | +12.4% | $1.6B | $1.5B | +3.7% |
| 2025-07-24 | $0.67 | $0.62 | +7.4% | $1.5B | $1.5B | +3.0% |
| 2025-04-23 | $0.64 | $0.60 | +7.4% | $1.4B | $1.4B | +0.9% |
| 2025-02-11 | $0.59 | $0.55 | +7.1% | $1.4B | $1.4B | +2.0% |
| 2024-10-24 | $0.67 | $0.67 | +0.8% | $1.4B | $1.5B | -12.3% |
| 2024-07-24 | $0.70 | $0.69 | +1.4% | $1.4B | $1.7B | -16.2% |
| 2024-04-25 | $0.66 | $0.64 | +3.1% | $1.6B | $1.6B | +1.8% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.07B | 5.44B | 5.01B | 5.38B | 5.23B | 4.39B | 4.35B | 3.72B | 3.44B | 2.96B | 2.49B | 2.32B |
| Net Income | 1.07B | 4.17B | 1.40B | 1.52B | 1.50B | 823.40M | 1.05B | 722.20M | 622.10M | 569.50M | 494.90M | 811.10M |
| EPS | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 | 1.32 | 1.68 | 1.15 | 0.98 | 0.89 | 0.77 | 1.27 |
| Total Assets | N/A | 13.06B | 9.36B | 8.29B | 8.50B | 7.24B | 6.49B | 5.32B | 5.70B | 4.51B | 4.06B | 3.52B |
| Total Debt | N/A | 700.00M | 685.10M | 691.30M | 690.30M | 694.90M | 678.80M | 593.80M | 1.04B | 822.30M | 596.90M | 598.10M |
| Cash & Equivalents | N/A | 3.05B | 1.13B | 769.00M | 862.80M | 1.18B | 1.18B | 714.10M | 818.30M | 930.10M | 718.40M | 653.80M |
| Operating Cash Flow | N/A | 542.30M | 895.80M | 1.22B | 1.73B | 1.05B | 1.18B | 926.80M | 1.00B | 704.40M | 549.70M | 1.02B |
| Free Cash Flow | N/A | 289.90M | 629.50M | 953.40M | 1.40B | 647.00M | 901.00M | 685.10M | 825.20M | 487.00M | 443.20M | 928.60M |
| FCF per Share | N/A | 0.49 | 1.04 | 1.54 | 2.25 | 1.04 | 1.44 | 1.09 | 1.30 | 0.76 | 0.69 | 1.45 |
| Book Value | N/A | 10.00B | 6.65B | 5.81B | 5.84B | 4.57B | 4.15B | 3.14B | 2.99B | 2.62B | 2.50B | 2.19B |
| Cash & ST Investments | N/A | 3.98B | 1.63B | 1.22B | 1.47B | 1.40B | 1.52B | 956.50M | 1.34B | 1.27B | 1.22B | 1.44B |
| ROC Equity | N/A | 0.42 | 0.21 | 0.26 | 0.26 | 0.18 | 0.25 | 0.23 | 0.21 | 0.22 | 0.20 | 0.37 |